Related Experiment Video
Updated: Jun 6, 2025
04:20
Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer
Published on: February 9, 2024
878
SIGMAR1 Knockdown Enhances Oral Cancer Cell Chemosensitivity to Cisplatin via Decreased PD-L1 Expression
Pablo Shimaoka Chagas1,2, Cristiana Bernadelli Garcia1, Lucas Oliveira Sousa1
1Department of Clinical Analyses, Toxicology and Food Sciences, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, Ribeirão Preto 14040-903, SP, Brazil.
International Journal of Molecular Sciences
|November 27, 2024
Summary
Sigma1 receptor (SIGMAR1) overexpression correlates with poor survival in oral cancer. Inhibiting SIGMAR1 reduces PD-L1 and enhances cisplatin sensitivity, suggesting SIGMAR1 as a potential therapeutic target for oral cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Aberrant Sigma1 receptor (SIGMAR1) expression is linked to various diseases, including cancer.
- The role of SIGMAR1 in oral cancer (OC) progression remains largely unexplored.
Purpose of the Study:
- To investigate the impact of SIGMAR1 knockdown in oral cancer cells.
- To explore the correlation between SIGMAR1, PD-L1, and patient survival in oral cancer.
Main Methods:
- Analysis of human oral cancer samples and cell lines.
- In vitro assays to assess the effects of SIGMAR1 inhibition.
- Evaluation of PD-L1 expression and apoptosis induction.
Main Results:
- SIGMAR1 overexpression is associated with poorer survival rates in oral cancer patients.
- SIGMAR1 expression positively correlates with PD-L1 overexpression in oral cancer.
- SIGMAR1 inhibition decreases PD-L1 expression and enhances oral cancer cell sensitivity to cisplatin via increased apoptosis.
Conclusions:
- SIGMAR1 plays a significant role in oral cancer progression and immune evasion.
- Targeting SIGMAR1 may represent a viable therapeutic strategy for oral cancer management.
- SIGMAR1 knockdown sensitizes oral cancer cells to chemotherapy, offering a potential combination therapy approach.
